Patients who completed two 12-week, double-blind, placebo-controlled, randomized studies had the option to enter a 40-week, open-label extension study with flexible dosing of VESIcare. 91% (1637/1802) of eligible patients chose to enter the 40-week safety study¹⁷.
Patients received VESIcare 5 mg once daily for the first 4 weeks of the 40-week extension study. At subsequent visits, based on efficacy and tolerability, patients were offered the option to adjust the dose between 5 mg and 10 mg. 81% of patients remained on VESIcare throughout an open-label extension study.

To help ensure patient compliance with a treatment course that includes VESIcare, you might consider telling your patients the following:

• VESIcare improves incontinence, urgency, and frequency.¹⁵ No OAB medication—VESIcare included—is indicated for nocturia.
• All OAB medications, including VESIcare, take time to work. Symptom improvement might be seen in as little as two weeks, or it might take more time.²¹
• Once symptoms improve, patients should continue to take one VESIcare dose once daily, to ensure that the improvements persist.

Treating OAB takes time. It is important that your patients know this from the beginning of treatment, so that they continue to follow the course of treatment that you prescribe even if, after a few days, they have noticed no significant improvement in symptoms.